Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Bullboard (TSX:MDNA)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Comment by Galaxym31on Mar 18, 2024 3:48pm

RE:RE:Out with the weak eh .

I bought this all the way from 1.35 down to .24 when they left Nasdaq which was a good move over a roll back . Made for some cheap stock . If they can outdo Keytruda than  blue sky .eh .40 us and ...more  
118
Discussion
Comment by Brianw21on Mar 18, 2024 3:27pm

RE:Out with the weak eh .

I have a fair amount of this stock.  They needed to get rid of the CEO which they did.  Clinical trials seem to be going well.  Any thoughts on how close we might be to some real market ...more  
101
Discussion
Post by Galaxym31on Mar 05, 2024 9:49am

A positive update and this rockets , look at Viking

12$ to 99$ on positive weight loss drug .My target  is 40 $ US .
90
Comment by Galaxym31on Feb 26, 2024 11:57am

RE:RE:No volume , no stock . Is this company that tightly

Someone go in for a million shares . Do it .
41
Discussion
Comment by windymayor1on Feb 26, 2024 10:05am

RE:No volume , no stock . Is this company that tightly

Hottest biotech in Cdn?!  only took 2 years. Now can they re list on NASDAQ?
59
Discussion
Post by Galaxym31on Feb 26, 2024 9:57am

No volume , no stock . Is this company that tightly

 held ? I think the powers that be no what this tech is worth now .
56
Discussion
Comment by windymayor1on Feb 15, 2024 1:41pm

RE:Can we just shoot up to the last PP price , I think it

Great having 2 trials 11 & 55, News on a MDNA 55 partner for phase 3 would be nice as well.  What's all this worth to Big Pharma if they hit on 2 drugs within the next year.  $Bs ...more  
146
Discussion
Comment by ENEMENEMYNEMOon Feb 15, 2024 8:32am

RE:I like this .

Keytruda 30 billion/yr sales.  Patent expires 2028. Merck needs a reformulation.  Addition of MDMA-11 (if trial shows success) as a combination  drug would give Merck an extra 20 years ...more  
106
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next